Breaking
Aid Ops

Scientists Find Immune Target for CALR-Mutant Blood Cancers

Scientists Find Immune Target for CALR-Mutant Blood Cancers - calr-mutant blood cancers
Scientists at Karl Landsteiner University discovered a process involving natural killer cells for treating chronic blood cancers.

Scientists at Karl Landsteiner University (KL Krems) have uncovered an immune system process that may open new avenues for treating specific types of chronic blood cancers. Their research reveals that natural killer (NK) cells, key for eliminating cancerous cells, largely maintain their ability to target abnormal cells in individuals with a particular genetic variant of myeloproliferative neoplasms (MPNs).

Immune challenges in blood disorders

MPNs are long-term conditions where the bone marrow overproduces blood cells. Depending on the specific type, patients face risks such as severe blood clots, bone marrow fibrosis, or progression to acute myeloid leukemia. Current treatments focus on symptom management and complication prevention but rarely achieve complete remission. Genetic variations among patients, including mutations in the calreticulin (CALR) protein, can affect treatment outcomes. While immune system dysfunction is a known feature of MPNs, the impact of CALR mutations on immune responses remained poorly understood.

A team from the Department of Pharmacology at KL Krems, led by Professor Dagmar Stoiber-Sakaguchi, explored whether these genetic differences could guide more precise treatments. They compared NK cells from patients with CALR mutations to those with JAK2 gene mutations. The study found that NK cells in JAK2-mutant patients were less functional, whereas those in CALR-mutant patients retained their capacity to release agents that destroy abnormal cells.

Focusing on immune responses

However, NK cells in CALR-mutant patients exhibited abnormally high levels of TIGIT, a receptor that dampens immune activity. Additional tests revealed raised levels of CD112, a TIGIT activator, on blood-forming precursor cells in these patients. Researchers also identified increased concentrations of several immune-regulating proteins in their blood. These observations indicate that CALR-mutant MPNs can both activate NK cells and simultaneously trigger signals that hinder their cancer-fighting ability.

To test whether this inhibition could be overcome, researchers used an antibody to block TIGIT. Laboratory experiments demonstrated that NK cells became more effective at eliminating abnormal cells. In an experimental model of CALR-mutant disease, antibody treatment showed potential in reducing raised platelet counts, a hallmark of this MPN type.

Study co-first authors Associate Professor Agnieszka Witalisz-Siepracka and Theresa Harm noted that these findings lay the groundwork for further investigation into TIGIT blockade as a supplementary treatment for CALR-mutant MPNs. This strategy aims to enhance patients’ immune systems rather than directly targeting mutated cells. The research remains in the preclinical phase and requires validation through larger studies and additional experiments.

blood cancers oncology research treatments
Afiqah Nordin

Leave a Reply

Your email address will not be published. Required fields are marked *